

3rd ANNUAL
GENITOURINARY
ONCOLOGY CONSORTIUM
MEETING 2026



GU
Oncology
EDUCATION ALLIANCE

SPEAKER BIOGRAPHIES




Pedro C. Barata, MD, MSc, FACP

Pedro Barata, MD, MSc, FACP is board-certified, fellowship-trained medical oncologist at University Hospitals Seidman Cancer Center and an Associate Professor of Medicine at Case Western Reserve University. Dr Barata serves as the director of the clinical genitourinary medical oncology research program and the co-leader of the genitourinary disease team at UH Seidman Cancer Center. Dr. Barata also holds the Miggo chair in clinical research. Dr. Barata is a clinical trialist and his research interests include cancer genomic profiling and novel therapeutics for genitourinary tumors.



Shilpa Gupta, MD

Dr. Shilpa Gupta is a genitourinary medical oncologist at Cleveland Clinic's Taussig Cancer Institute and Professor of Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. She has extensive experience in clinical trials across genitourinary cancers, including early-phase studies and pivotal trials in bladder and prostate cancers. Her research interests are understanding biomarkers of response and resistance to therapies in bladder and prostate cancers. She has received several federally funded grants in bladder and prostate cancer, including Department of Defense and R01 grants.



Spyridon Basourakos, MD, MS

Spyridon Basourakos, MD, MS, is a urologic oncologist at University Hospitals and Assistant Professor of Urology at Case Western Reserve University, specializing in open and robotic surgery for prostate, bladder, kidney, penile, and testicular cancers. Born in Athens, Greece, he earned his medical degree from University of Ioannina. He trained at MD Anderson (research fellowship), Weill Cornell (urology residency), and Mayo Clinic (Society of Urologic Oncology fellowship), where he earned a master's in clinical and translational science. His research has appeared in the New England Journal of Medicine and European Urology. He lives in Cleveland with his wife and children.



Jason Brown, MD

Jason Robert Brown, MD, is a genitourinary medical oncologist in the Division of Solid Tumor Oncology at University Hospitals Cleveland Medical Center and appointed as an Associate Professor at the Case Western School of Medicine. He earned his PhD in Experimental Pathology and his MD at Yale University. Dr. Brown completed both his residency and post-graduate training in Hematology and Oncology at the University of Michigan Medical School. Dr. Brown is board-certified in Medical Oncology. He is a Member of The American Society of Clinical Oncology. His research interests include early-stage clinical trials and application of novel biomarkers in genitourinary cancers. He is also associate program director of the fellowship program, and mentors students, residents, and fellows in various research projects.




Adam Calaway, MD

Adam Calaway, MD, is an Associate Professor at Case Western Reserve University/University Hospitals and the former Division Chief of Urologic Oncology and Co-Lead of Genitourinary Disease Team at UH Seidman Cancer Center. His clinical and academic focus is urothelial carcinoma and testicular cancer. Dr. Calaway did his training, including residency, fellowship, and Masters of Public Health in epidemiology at Indiana University.

**Demitrios Dedousis, MD**

Demitrios Dedousis, MD, is a board-certified hematologist/oncologist and geneticist. He works as a genitourinary oncologist and cancer geneticist associate staff physician at Cleveland Clinic. Dr. Dedousis is passionate about elucidating the genetic underpinnings of malignancy in order to improve oncologic risk stratification, screening, diagnosis, and treatment. His ultimate goal is to improve the care and lives of those with hereditary predispositions to cancer as a clinical investigator.

**Jorge A. Garcia, MD, MSc, FACP**


Jorge A. Garcia, MD, MSc, FACP, is Professor of Medicine and Urology at Case Western Reserve University, holding the George and Edith Richman Distinguished Scientist Chair. He serves as Chair of the Division of Solid Tumor Oncology at University Hospitals Seidman Cancer Center and is a senior leader within the Case Comprehensive Cancer Center. An internationally recognized medical oncologist, Dr. Garcia focuses on prostate, kidney, and bladder cancers, with research spanning developmental therapeutics, immuno-oncology, and biomarker-driven clinical trials. He has authored more than 300 peer-reviewed publications and previously served as Chair of the FDA's Oncologic Drugs Advisory Committee.

**Angela Jia, MD, PhD**

Angela Jia, MD, PhD, is an Assistant Professor and Residency Program Director in the Department of Radiation Oncology at Case Western Reserve University. She also serves as the Director of Genitourinary Radiation Oncology and Co-Lead of the GU Disease Team at University Hospitals Seidman Cancer Center. She completed her medical training at Weill Cornell Medicine, doctoral training in Pathology at Columbia University, and residency training at Johns Hopkins University, where she served as Chief Resident. Her research interests include clinical studies of targeted radiopharmaceuticals, the development and validation of prognostic and predictive biomarkers, and clinical trials to optimize the potential of radiotherapy against endpoints that are the most important to patients.

**Murilo de Almeida Luz, MD**

Murilo de Almeida Luz, MD, is a Urologic Oncologist at University Hospitals Cleveland Medical Center and Associate Professor of Medicine at Case Western Reserve University. He is dedicated to all aspects related to urological cancer: research, diagnosis, treatment, teaching, and outcome evaluation. He also has a strong background in and is currently active as an investigator in clinical trials for new cancer treatments. He is a strong healthcare services professional with a Uro-Oncology and Robotic/MIS in Urology - Clinical Fellowship at McGill University.

**Prateek Mendiratta, MD**

Dr. Mendiratta is a Community Oncologist at University Hospitals Seidman Cancer Center. His background includes Internal Medicine at Northwestern, Fellowship at Duke, and Experimental Medicine and Therapeutics Fellowship at Cleveland Clinic.

**Shalini Moningi, MD**

Dr. Shalini Moningi is a radiation oncologist specializing in genitourinary cancers at Cleveland Clinic Taussig Cancer Center. She completed medical school at Johns Hopkins and residency training at MD Anderson Cancer Center. Her clinical and research interests include prostate cancer, oligometastatic disease, clinical trials, and the application of artificial intelligence in oncology. She is actively involved in national research collaborations, education, and mentorship, and currently serves as Fellowship Director. Dr. Moningi has authored numerous publications and presents regularly at national and international oncology meetings.

**Moshe Ornstein, MD, MA**

Dr. Moshe Ornstein is the program leader of genitourinary medical oncology at Cleveland Clinic Taussig Cancer Institute. He attended graduate school for biotechnology at Columbia University, followed by medical school at SUNY Stony Brook. He completed his internal medicine residency and hematology/oncology fellowship at Cleveland Clinic. Dr. Ornstein's clinical practice and research are focused on cancers of the genitourinary system. He is actively involved in multiple clinical trials and translational research.

**Santosh Rao, MD**

Santosh Rao, MD, ABOIM is a board-certified, fellowship-trained medical oncologist at Cleveland Clinic and an Associate Professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine. Dr. Rao serves as Chief of Staff of Hematology and Oncology at Cleveland Clinic Akron General Hospital and specializes in genitourinary oncology at Cleveland Clinic Taussig Cancer Center. Dr. Rao has a long-term interest in Integrative Oncology, serving as director of Integrative Oncology programs and recently serving as the Immediate Past-President of the Society for Integrative Oncology.

**Amy M Reese, MD, FACP**

Amy M Reese, MD, FACP, is board-certified, hematologist/medical oncologist employed by Northern Ohio Medical Specialists and an Affiliate Professor of Medicine at Case Western Reserve University. Dr. Reese completed fellowship at the National Capital Consortium at Walter Reed Military Medical Center and served as a Navy physician for over fifteen years prior to relocating to northern Ohio to practice community oncology. She currently serves as Medical Director of Oncology at University Hospitals Seidman Cancer Center at Firelands in Sandusky, Ohio, and Medical Director of Oncology at Magruder Hospital in Port Clinton, Ohio.

**Soumyajit (Soum) Roy, MBBS, MSc**

Dr. Soumyajit (Soum) Roy is Assistant Professor of Radiation Oncology at Case Western Reserve University and a radiation oncologist at University Hospitals Seidman Cancer Center in Cleveland, Ohio. He specializes in genitourinary malignancies, with a particular clinical and research focus on prostate cancer. His research integrates clinical outcomes, biostatistics, artificial intelligence, genomics, and spatial biology to develop biomarkers that can better personalize radiation and systemic therapy. Dr. Roy has formal training in biostatistics and epidemiology and is also pursuing graduate training in bioinformatics. He has published extensively in prostate cancer, including first-author work in *Nature Communications*, *European Urology*, and the *Journal of Clinical Oncology*, and serves as a peer reviewer for several leading oncology and urology journals. He is also a recipient of the Prostate Cancer Foundation Young Investigator Award (PCF YIA). His long-term research goal is to develop and prospectively validate multimodal biomarkers that improve treatment selection for patients with prostate cancer.

**Sree Harsha Tirumani, MD, FSAR**

Dr. Sree Harsha Tirumani is Associate Professor of Radiology at Case Western Reserve University School of Medicine and serves at University Hospitals Cleveland Medical Center as Vice Chair for Clinical Research, Division of Abdominal Imaging, and Director of the Abdominal Imaging Fellowship. He serves as the lead radiologist for genitourinary multidisciplinary team meetings at UHCMC and University Hospitals Seidman Cancer Center. His clinical and research expertise focuses on abdominal MRI, kidney and prostate cancer imaging, and the clinical translation of MR Fingerprinting.

**Chris Weight, MD**

Professor Chris Weight is the Vice Chair over Research and Center Director for Urologic Oncology at Cleveland Clinic. He splits his time between patient care, education, and research. He directs the Society of Urologic Oncology Fellowship at Cleveland Clinic and the AIM-HI lab. He is an NIH funded researcher focusing on GU malignancies. Nearly 10 years ago he founded a non-profit organization called Climb 4 Kidney Cancer to elevate and celebrate kidney cancer patients while raising money for kidney cancer research.
